Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
MAIA Biotechnology is a clinical-stage oncology company developing THIO, a telomerase-targeting immunotherapy for cancer treatment. The company is pre-revenue with a single lead asset in clinical development, focused on solid tumors including non-small cell lung cancer. With $0.1B market cap and negative cash flow of approximately $20M annually, MAIA is a high-risk, binary-outcome biotech dependent on clinical trial results and capital markets access for survival.
MAIA operates a classic clinical-stage biotech model with no current revenue generation. The company is burning cash to fund Phase 2/3 clinical trials of THIO, a telomerase-targeting immunotherapy. Value creation depends entirely on successful clinical trial outcomes, regulatory approval, and eventual commercialization or partnership deals. The business model requires continuous equity financing until reaching profitability, which is typically 7-10 years post-founding for successful biotechs. Current burn rate of approximately $20M annually against minimal cash generation creates significant dilution risk for existing shareholders.
THIO clinical trial data releases - interim analyses, safety updates, efficacy endpoints for ongoing Phase 2/3 studies
FDA regulatory interactions - IND approvals, clinical hold risks, breakthrough therapy designation potential
Capital raises and dilution events - equity offerings, warrant exercises, ATM programs given 1.18x current ratio
Partnership or licensing announcements - pharma collaborations for development/commercialization rights
Competitive clinical data from rival telomerase or immunotherapy programs
Biotech sector sentiment and small-cap risk appetite - 92% 3-month return suggests momentum/speculation
Binary clinical trial risk - single asset (THIO) concentration means trial failure could render equity worthless; no diversified pipeline to offset development setbacks
Capital markets dependency - with 1.18x current ratio and $20M annual burn, company requires continuous equity financing; adverse market conditions could force fire-sale dilution or bankruptcy
Regulatory approval uncertainty - oncology drugs face 10-15% Phase 2 to approval success rates; FDA requirements may expand beyond current trial designs
Telomerase mechanism validation risk - if THIO's mechanism proves ineffective or unsafe, entire platform value evaporates with no pivot options
Large pharma immunotherapy competition - Merck, BMS, Roche have vastly superior resources for oncology development and can out-spend MAIA 100:1 on competing mechanisms
Checkpoint inhibitor dominance - established PD-1/PD-L1 therapies set high efficacy bars; THIO must demonstrate differentiation or combination value
Biotech peer competition for capital - hundreds of clinical-stage oncology companies compete for limited investor dollars; MAIA's $0.1B market cap limits visibility
Liquidity crisis risk - 1.18x current ratio provides minimal buffer; one failed financing round could trigger insolvency within 12-18 months
Dilution spiral - negative 715% ROE and continuous losses force equity issuance; existing shareholders face severe dilution if stock price remains depressed
Going concern uncertainty - auditors may flag going concern issues if cash runway drops below 12 months without secured financing commitments
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, capital markets access for financing is highly sensitive to risk appetite, which correlates with economic conditions. During recessions, small-cap biotech funding becomes scarce, creating existential risk for pre-revenue companies. The company's ability to raise capital at reasonable valuations depends more on biotech sector sentiment than broad economic health.
High sensitivity through multiple channels: (1) Rising rates compress biotech valuations as distant cash flows are discounted more heavily - particularly severe for pre-revenue assets with 7-10 year monetization timelines. (2) Higher rates reduce speculative capital flows into high-risk small-cap biotechs, making equity raises more dilutive. (3) Cash held on balance sheet earns higher returns in rising rate environments (minor positive offset). The 1537.8x price/book ratio indicates extreme valuation compression risk from rate increases. Federal funds rate movements directly impact investor willingness to fund cash-burning clinical stories.
Minimal direct credit exposure - company has zero debt (0.00 debt/equity ratio) and no credit-dependent operations. However, indirect exposure exists through equity capital markets: tighter credit conditions reduce institutional risk appetite for speculative biotech investments, making future financing rounds more challenging and dilutive.
momentum/speculation - The 92% 3-month return with no revenue or near-term catalysts indicates retail speculation and momentum trading rather than fundamental value investing. Attracts high-risk biotech specialists willing to accept binary outcomes, day traders riding volatility, and investors betting on clinical trial lottery tickets. Not suitable for value or income investors given negative cash flows and zero dividends. Institutional ownership likely minimal given $0.1B market cap below most fund minimums.
high - Clinical-stage single-asset biotechs exhibit extreme volatility with 50-100% intraday swings common around data releases. The 92% 3-month gain followed by sector-typical drawdown risk exemplifies this pattern. Beta likely 2.0+ versus biotech indices. Options market (if available) would show elevated implied volatility. Illiquidity in $0.1B market cap exacerbates price swings on modest volume.